REXULTI (Otsuka America Pharmaceutical, Inc.)
Welcome to the PulseAid listing for the REXULTI drug offered from Otsuka America Pharmaceutical, Inc.. This Atypical Antipsychotic [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Otsuka America Pharmaceutical, Inc. |
| NON-PROPRIETARY NAME: | brexpiprazole |
| SUBSTANCE NAME: | BREXPIPRAZOLE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Atypical Antipsychotic [EPC] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-07-10 |
| END MARKETING DATE: | 0000-00-00 |
REXULTI HUMAN PRESCRIPTION DRUG Details:
| Item Description | REXULTI from Otsuka America Pharmaceutical, Inc. |
| LABELER NAME: | Otsuka America Pharmaceutical, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 0.25(mg/1) |
| START MARKETING DATE: | 2015-07-10 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 59148-035_9d263d31-21bf-4b5d-8893-b7ccc3c3fe0c |
| PRODUCT NDC: | 59148-035 |
| APPLICATION NUMBER: | NDA205422 |
Other BREXPIPRAZOLE Pharmaceutical Manufacturers / Labelers:
